MaoShengGe

Pendle (PENDLE) Crisis Investment In-Depth Report
The only interest rate king in DeFi, down 86%, should you buy the dip?
First, the conclusion: $PENDLE is a highly capable product, a monopolized track, but highly cycle-sensitive DeFi protocol. The current price of $1.07 is within the fair valuation center—not an extreme mispricing, but if you believe in the long-term growth of the DeFi interest rate market, the risk-reward ratio here is 1:4.
Below is the full analysis, with data cross-verified from DeFiLlama, CoinGecko, and CMC.
A one-sentence explanation of what Pendle is
Splitting

EigenLayer ($EIGEN ‌EIGEN) $8.7 billion TVL, $100 million market cap. This could be the biggest value mismatch in crypto history—or the biggest value trap.
Using a crisis investment model with 15 dimensions plus 12 valuation methods, I deeply dissected EigenLayer (EIGEN).
This token plummeted from $5.65 by 97.3% to $0.15, just hitting a new all-time low.
Fear and greed index is 13, extreme fear. 83% of people are bearish.
But it holds $8.7 billion in assets locked, making it the third-largest protocol in DeFi.
Is this a "good company wrongly killed by sentiment," or a "tech without re

$BEAM: The market is selling a base editing empire worth 1.35 billion dollars — this could be the most underestimated biotech asset by 2026
The conclusion is only one sentence: the market is selling a therapeutic platform with NEJM-published data, FDA accelerated approval pathway, and the global exclusive IP of the base editing inventor at nearly cash value.
Below is the complete investment logic chain. All data has been cross-verified, and every number has a source.
1. First, the most important numbers
$BEAM ‌BEAM current stock price ~$24.5
Market cap ~$2.5 billion
Cash + marketa

The gene editing therapy invented by Nobel laureates, why did the market only assign a 40% valuation?
A primary school math problem:
CRISPR Therapeutics has a current market value of $4.5 billion. Cash on hand is $2.5 billion. $4.5 billion - $2.5 billion = $2 billion.
What is the market pricing in?
The world's first FDA-approved CRISPR gene editing therapy + 6 active clinical pipelines + Nobel-level intellectual property + exclusive partnership with Vertex valued at $110 billion.
But rebuilding these assets from scratch would cost at least $7.2 billion.
$2 billion vs $7.2 billion. Less than a

Deep Investment Research: Nobel Prize-Winning Gene Editing Therapy, Why Is the Market Only Valuing It at a Quarter of Its Price?
A simple arithmetic problem:
CRISPR Therapeutics has a current market cap of $4.5 billion. Cash on hand is $2.5 billion. $4.5 billion - $2.5 billion = $2 billion.
What is the market pricing at $2 billion?
The world's first FDA-approved CRISPR gene editing therapy + 6 active clinical pipelines + Nobel Prize-level intellectual property + exclusive partnership with Vertex, valued at $110 billion.
But rebuilding these assets from scratch would cost at least $7.2 billion.

Tempus AI, one of the most hotly contested stocks in the U.S. stock market right now.
On one side, Cathie Wood has it as the top holding in the ARKG fund (9.49% weight), aggressively adding shares at the $43 price level.
On the other side, there are short reports from Spruce Point, collective securities lawsuits, the CEO selling over $34 million, and an 18% short interest.
One side is the world's largest AI medical data platform. The other side is questioning "funds flowing back" and swirling related-party transactions.
I did one thing: ignoring stock price and sentiment, just asking o

TempusAI Deep Investment Research: Woodie's Largest Holding, Biggest Short Target—How Is the AI Medical Deal Calculated?
Tempus AI, one of the most volatile stocks in the US market right now.
On one side, Cathie Wood has it as the top holding in ARKG (9.49% weight), aggressively adding shares at around $43. On the other side, there are the Spruce Point short report, class-action lawsuits, CEO selling over $34 million, and an 18% short interest.
On one hand, it’s the world’s largest AI healthcare data platform. On the other, there are questions about capital backflow and related-party transacti